CTCs from breast cancer patients with human epidermal growth factor receptor (HER2)-positive tumors exhibit increased expression of HER2, which can help predict the response to HER2-targeted therapies like trastuzumab (Herceptin) [85]. This evidence concerns the gene ERBB2 and breast carcinoma.